Complement in Pregnancy: A Delicate Balance

American Journal of Reproductive Immunology

Volumn 69, Issue 1, 2013, Pages 3-11

  Denny, Kerina J ^a   Woodruff, Trent M ^a   Taylor, Stephen M ^a   Callaway, Leonie K ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

C5a; Preeclampsia; Preterm birth; Recurrent miscarriage

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; MANNAN BINDING LECTIN; PRAVASTATIN; RECOMBINANT VASCULOTROPIN;

ANTIGEN ANTIBODY COMPLEX; BLOOD VESSEL PERMEABILITY; CELL ACTIVATION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INNATE IMMUNITY; NONHUMAN; OPSONIZATION; OXIDATIVE STRESS; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SPONTANEOUS ABORTION; TH1 CELL; TH1 TH2 BALANCE; TH2 CELL;

ABORTION, HABITUAL; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; FEMALE; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; PRE-ECLAMPSIA; PREGNANCY; PREMATURE BIRTH;

EID: 84870734684     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12000     Document Type: Review

References (85)

1. Suzuki MM, Satoh N, Nonaka M: C6-like and C3-like molecules from the cephalochordate, amphioxus, suggest a cytolytic complement system in invertebrates. J Mol Evol 2002; 54:671-679.
2. Azumi K, De Santis R, De Tomaso A, Rigoutsos I, Yoshizaki F, Pinto MR, Marino R, Shida K, Ikeda M, Ikeda M, Arai M, Inoue Y, Shimizu T, Satoh N, Rokhsar DS, Du Pasquier L, Kasahara M, Satake M, Nonaka M: Genomic analysis of immunity in a Urochordate and the emergence of the vertebrate immune system: "waiting for Godot". Immunogenetics 2003; 55:570-581.
3. Al-Sharif WZ, Sunyer JO, Lambris JD, Smith LC: Sea urchin coelomocytes specifically express a homologue of the complement component C3. J Immunol 1998; 160:2983-2997.
4. Dunkelberger JR, Song WC: Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34-50.
5. Manthey HD, Woodruff TM, Taylor SM, Monk PN: Complement component 5a (C5a). Int J Biochem Cell Biol 2009; 41:2114-2117.
6. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA: A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 2000; 37:407-412.
7. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, Huber-Lang M: Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632:71-79.
8. Carroll MC: The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5:981-986.
9. Chaouat G: The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol 2007; 29:95-113.
10. Mor G, Cardenas I: The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010; 63:425-433.
11. Baines MG, Millar KG, Mills P: Studies of complement levels in normal human pregnancy. Obstet Gynecol 1974; 43:806-810.
12. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, Edwin S, Kim YM, Hong JS, Mazor M: Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med 2005; 17:239-245.
13. Hopkinson ND, Powell RJ: Classical complement activation induced by pregnancy: implications for management of connective tissue diseases. J Clin Pathol 1992; 45:66-67.
14. Faulk WP, Jarret R, Keane M, Johnson PM, Boackle RJ: Immunological studies of human placentae: complement components in immature and mature chorionic villi. Clin Exp Immunol 1980; 40:299-305.
15. Tedesco F, Radillo O, Candussi G, Nazzaro A, Mollnes TE, Pecorari D: Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol 1990; 80:236-240.
16. Weir PE: Immunofluorescent studies of the uteroplacental arteries in normal pregnancy. Br J Obstet Gynaecol 1981; 88:301-307.
17. Girardi G, Prohaszka Z, Bulla R, Tedesco F, Scherjon S: Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol 2011; 48:1621-1630.
18. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS: Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37:733-737.
19. Pellis V, De Seta F, Crovella S, Bossi F, Bulla R, Guaschino S, Radillo O, Garred P, Tedesco F: Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin Exp Immunol 2005; 139:120-126.
20. Girardi G, Bulla R, Salmon JE, Tedesco F: The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43:68-77.
21. Conroy AL, McDonald CR, Silver KL, Liles WC, Kain KC: Complement activation: a critical mediator of adverse fetal outcomes in placental malaria? Trends Parasitol 2011; 27:294-299.
22. Holmberg V, Onkamo P, Lahtela E, Lahermo P, Bedu-Addo G, Mockenhaupt FP, Meri S: Mutations of complement lectin pathway genes MBL2 and MASP2 associated with placental malaria. Malar J 2012; 11:61.
23. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H: A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000; 287:498-501.
24. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP: Control of the complement system. Adv Immunol 1996; 61:201-283.
25. Francis J, Rai R, Sebire NJ, El-Gaddal S, Fernandes MS, Jindal P, Lokugamage A, Regan L, Brosens JJ: Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006; 12:435-442.
26. Wirstlein P, Mikolajczyk M, Skrzypczak J: Assessment of the transcription levels for the complement activation control system in eutopic endometrium in women with two or more consecutive miscarriages of unknown etiology. Folia Histochem Cytobiol 2010; 48:328-332.
27. Pacheco LD, Hankins GD, Costantine MM, Anderson GD, Pawelczyk E, Nowicki S, Nowicki BJ: The role of human decay-accelerating factor in the pathogenesis of preterm labor. Am J Perinatol 2011; 28:565-570.
28. Rai R, Regan L: Recurrent miscarriage. Lancet 2006; 368:601-611.
29. Wilcox AJ, Weinberg CR, O'Connor JF et al.: Incidence of early loss of pregnancy. N Engl J Med 1988; 319:189-194.
30. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-220.
31. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644-1654.
32. Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ: Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107:423-429.
33. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G: Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:2423-2431.
34. Derksen RH, Khamashta MA, Branch DW: Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50:1028-1039.
35. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222-1226.
36. Girardi G: Complement inhibition keeps mothers calm and avoids fetal rejection. Immunol Invest 2008; 37:645-659.
37. Sugiura-Ogasawara M, Nozawa K, Nakanishi T, Hattori Y, Ozaki Y: Complement as a predictor of further miscarriage in couples with recurrent miscarriages. Hum Reprod 2006; 21:2711-2714.
38. Micheloud D, Sarmiento E, Teijeiro R, Jensen J, Rodríguez Molina JJ, Fernández-Cruz E, Carbone J: Hypocomplementemia in the absence of autoantibodies in women with recurrent pregnancy loss. Allergol Immunopathol 2007; 35:90-94.
39. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:2165-2175.
40. Clark DA, Foerster K, Fung L, He W, Lee L, Mendicino M, Markert UR, Gorczynski RM, Marsden PA, Levy GA: The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. Mol Hum Reprod 2004; 10:99-108.
41. Foerster K, He W, Manuel J, Bartczak A, Liu M, Markert UR, Levy GA, Clark DA: LPS-induced occult loss in mice requires FGL2. Am J Reprod Immunol 2007; 58:524-529.
42. Clark DA, Chaouat G, Banwatt D, Friebe A, Arck PC: Ecology of danger-dependent cytokine-boosted spontaneous abortion in the CBA x DBA/2 mouse model: II. Fecal LPS levels in colonies with different basal abortion rates. Am J Reprod Immunol 2008; 60:529-533.
43. Clark DA, Manuel J, Lee L, Chaouat G, Gorczynski RM, Levy GA: Ecology of danger-dependent cytokine-boosted spontaneous abortion in the CBA x DBA/2 mouse model. I. Synergistic effect of LPS and (TNF-alpha + IFN-gamma) on pregnancy loss. Am J Reprod Immunol 2004; 52:370-378.
44. Yu G, Sun Y, Foerster K, Manuel J, Molina H, Levy GA, Gorczynski RM, Clark DA: LPS-induced murine abortions require C5 but not C3, and are prevented by upregulating expression of the CD200 tolerance signaling molecule. Am J Reprod Immunol 2008; 60:135-140.
45. Girardi G: Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol 2009; 82:126-131.
46. Redecha P, van Rooijen N, Torry D, Girardi G: Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009; 113:4101-4109.
47. Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes of preterm birth. Lancet 2008; 371:75-84.
48. McCormick MC: The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med 1985; 312:82-90.
49. Slattery MM, Morrison JJ: Preterm delivery. Lancet 2002; 360:1489-1497.
50. Wei SQ, Fraser W, Luo ZC: Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol 2010; 116:393-401.
51. Lappas M, Woodruff T, Taylor S, Permezel M: Complement c5a regulates prolabor mediators in human placenta. Biol Reprod 2012; 86:190.
52. Elovitz MA, Wang Z, Chien EK, Rychlik DF, Phillippe M: A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4. Am J Pathol 2003; 163:2103-2111.
53. Gonzalez JM, Franzke CW, Yang F, Romero R, Girardi G: Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am J Pathol 2011; 179:838-849.
54. Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC, Salmon JE, Van Hecke TM, Holers VM: Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 2008; 199:354e1-e8.
55. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM: Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol 2011; 117:75-83.
56. Caucheteux SM, Kanellopoulos-Langevin C, Ojcius DM: At the innate frontiers between mother and fetus: linking abortion with complement activation. Immunity 2003; 18:169-172.
57. Soto E, Romero R, Richani K, Yoon BH, Chaiworapongsa T, Vaisbuch E, Mittal P, Erez O, Gotsch F, Mazor M, Kusanovic JP: Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection. J Matern Fetal Neonatal Med 2009; 22:983-992.
58. Woodruff TM, Nandakumar KS, Tedesco F: Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48:1631-1642.
59. Davey DA, MacGillivray I: The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158:892-898.
60. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33:130-137.
61. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S: Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.
62. Powe CE, Levine RJ, Karumanchi SA: Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123:2856-2869.
63. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R: Pre-eclampsia. Lancet 2010; 376:631-644.
64. Lynch AM, Salmon JE: Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010; 31:561-567.
65. Dekker G, Robillard PY: Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol 2007; 76:8-16.
66. Campbell DM, MacGillivray I, Carr-Hill R: Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92:131-140.
67. Einarsson JI, Sangi-Haghpeykar H, Gardner MO: Sperm exposure and development of preeclampsia. Am J Obstet Gynecol 2003; 188:1241-1243.
68. Kyrou D, Kolibianakis EM, Devroey P, Fatemi HM: Is the use of donor sperm associated with a higher incidence of preeclampsia in women who achieve pregnancy after intrauterine insemination? Fertil Steril 2010; 93:1124-1127.
69. Koelman CA, Coumans AB, Nijman HW, Doxiadis II, Dekker GA, Claas FH: Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol 2000; 46:155-166.
70. Chakravarty EF, Nelson L, Krishnan E: Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:899-907.
71. Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, Salmon JE, Holers VM: Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008; 198:385e1-e9.
72. Soto E, Romero R, Richani K, Espinoza J, Chaiworapongsa T, Nien JK, Edwin SS, Kim YM, Hong JS, Goncalves LF, Yeo L, Mazor M, Hassan SS, Kusanovic JP: Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med 2010; 23:646-657.
73. Lynch AM, Eckel RH, Murphy JR, Gibbs RS, West NA, Giclas PC, Salmon JE, Holers VM: Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol 2012; 206:428e1-e8.
74. Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, Davisson RL, Salmon JE: Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 2011; 79:331-339.
75. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
76. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911-919.
77. Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186-193.
78. Bulla R, Agostinis C, Bossi F, Rizzi L, Debeus A, Tripodo C, Radillo O, De Seta F, Ghebrehiwet B, Tedesco F: Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol 2008; 45:2629-2640.
79. Agostinis C, Bulla R, Tripodo C, Gismondi A, Stabile H, Bossi F, Guarnotta C, Garlanda C, De Seta F, Spessotto P, Santoni A, Ghebrehiwet B, Girardi G, Tedesco F: An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol 2010; 185:4420-4429.
80. Singh J, Ahmed A, Girardi G: Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011; 58:716-724.
81. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G: A new mouse model to explore therapies for preeclampsia. PLoS One 2010; 5:e13663.
82. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M: Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108:1451-1455.
83. Ahmed A, Williams D: Statins to ameliorate early on- set pre-eclampsia University of Birmingham (Accessed March 1, 2012, at http://www.stamp.bham.ac.uk)
84. Kusters DM, Lahsinoui HH, van de Post JA, Wiegman A, Wijburg FA, Kastelein JJ, Hutten BA: Statin use during pregnancy: a systematic review and meta-analysis. Exp Rev Cardiovasc Ther 2012; 10:363-378.
85. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V: Statins and pregnancy: between supposed risks and theoretical benefits. Drugs 2012; 72:773-788.